Search

Start Over Subjects COVID-19 Drug Treatment

1. Institutional review board (IRB) review of individual patient expanded access requests for investigational drugs and biological products during the COVID-19 public health emergency: guidance for IRBs and clinical investigators

Publication:
[Silver Spring, MD] : Oncology Center of Excellence, June 2020
Subject(s):
Biological Products -- therapeutic use
COVID-19 Drug Treatment
Drugs, Investigational
Ethics Committees, Research
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

3. COVID-19 public health emergency: general considerations for pre-IND meeting requests for COVID-19 related drugs and biological products : guidance for industry and investigators

Publication:
[Silver Spring, MD] : Center for Drug Evaluation and Research, May 2020
Subject(s):
Biological Products
COVID-19 Drug Treatment
Drug Approval
Drug Industry
Drugs, Investigational
Drug Evaluation, Preclinical
Investigational New Drug Application
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

8. Understanding coverage considerations for COVID-19 vaccines and treatments

Author(s):
Beleche, Trinidad, author
Bush, Laina, author
Finegold, Kenneth, 1957- author
Manocchio, Teresa, author
Pyda, Sarada, author
Samson, Lok Wong, author
Sommers, Benjamin D., author
Publication:
Washington, D.C. : Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, May 2023
Subject(s):
Cost Savings
COVID-19 Drug Treatment
COVID-19 -- economics
COVID-19 Vaccines -- economics
Insurance Coverage
United States

9. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

Author(s):
Whittington, Melanie D., author
Campbell, Jonathan D., author
Richardson, Marina, author
Nhan, Emily, author
McKenna, Avery, author
Agboola, Foluso, author
Pearson, Steven D., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2022
Subject(s):
Ambulatory Care -- economics
Antiviral Agents -- economics
COVID-19 Drug Treatment
Drug Combinations
Drug Costs
Lactams
Leucine
Nitriles
Proline
Ritonavir
United States

10. Understanding coverage considerations for COVID-19 vaccines and treatments

Author(s):
Beleche, Trinidad, author
Bush, Laina, author
Finegold, Kenneth, 1957- author
Manocchio, Teresa, author
Pyda, Sarada, author
Samsom, Lok Wong, author
Sommers, Benjamin D., author
Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, August 2022
Subject(s):
Cost Savings
COVID-19 -- economics
COVID-19 Drug Treatment
COVID-19 Vaccines -- economics
Insurance Coverage -- economics
Drug Approval
United States

11. COVID-19 antivirals utilization: geographic and demographic patterns of treatment in 2022

Author(s):
Murphy, Stephen J. (Stephen James), author
Samson, Lok Wong, author
Sommers, Benjamin D., author
Publication:
Washington, D.C. : Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, December 23, 2022
Subject(s):
Antiviral Agents -- therapeutic use
COVID-19 Drug Treatment
Drug Utilization -- statistics & numerical data
State Government
United States

13. Special assessment of outpatient treatments for COVID-19: final evidence report and meeting summary

Author(s):
Yeung, Kai, 1981- author
Whittington, Melanie D., author
Beinfeld, Molly, author
Mohammed, Rasheed, author
Wright, Abigail, (Of Institute for Clinical and Economic Review), author
Nhan, Emily, author
Fluetsch, Noemi, author
Richardson, Marina, (Of Institute for Clinical and Economic Review), author
Pearson, Steven D., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, May 10, 2022
Subject(s):
Ambulatory Care
COVID-19 Drug Treatment
Home Infusion Therapy
United States